David C Huang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3880605/publications.pdf

Version: 2024-02-01

234	38,707	3151 92	2743 192
papers	citations	h-index	g-index

241	241	241	33202
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL. Blood, 2022, 139, 1198-1207.	0.6	34
2	Pharmacologic Reduction of Mitochondrial Iron Triggers a Noncanonical BAX/BAK-Dependent Cell Death. Cancer Discovery, 2022, 12, 774-791.	7.7	18
3	The Lck inhibitor, AMG-47a, blocks necroptosis and implicates RIPK1 in signalling downstream of MLKL. Cell Death and Disease, 2022, 13, 291.	2.7	10
4	Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy. Blood, 2022, 140, 2127-2141.	0.6	28
5	The transcription factor IRF4 represses proapoptotic BMF and BIM to licence multiple myeloma survival. Leukemia, 2021, 35, 2114-2118.	3.3	18
6	Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X_L and BCL-2. Journal of Medicinal Chemistry, 2021, 64, 5447-5469.	2.9	5
7	PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling. Genome Medicine, 2021, 13, 58.	3.6	62
8	Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias. Blood, 2021, 137, 2721-2735.	0.6	75
9	TCF3 is epigenetically silenced by EZH2 and DNMT3B and functions as a tumor suppressor in endometrial cancer. Cell Death and Differentiation, 2021, 28, 3316-3328.	5.0	25
10	BCL2 and MCL1 inhibitors for hematologic malignancies. Blood, 2021, 138, 1120-1136.	0.6	78
11	Transcriptional silencing of fetal hemoglobin expression by NonO. Nucleic Acids Research, 2021, 49, 9711-9723.	6.5	7
12	Outcomes of patients with CLL sequentially resistant to both BCL2 and BTK inhibition. Blood Advances, 2021, 5, 4054-4058.	2.5	39
13	TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth. Nature Communications, 2021, 12, 5337.	5.8	14
14	Comprehensive characterization of single-cell full-length isoforms in human and mouse with long-read sequencing. Genome Biology, 2021, 22, 310.	3.8	83
15	Mesenchymal stromal cell apoptosis is required for their therapeutic function. Nature Communications, 2021, 12, 6495.	5.8	91
16	EBV BCL-2 homologue BHRF1 drives chemoresistance and lymphomagenesis by inhibiting multiple cellular pro-apoptotic proteins. Cell Death and Differentiation, 2020, 27, 1554-1568.	5.0	35
17	BH3 Mimetics for the Treatment of B-Cell Malignanciesâ€"Insights and Lessons from the Clinic. Cancers, 2020, 12, 3353.	1.7	12
18	Defining the susceptibility of colorectal cancers to BH3-mimetic compounds. Cell Death and Disease, 2020, 11, 735.	2.7	10

#	Article	IF	Citations
19	Potent Inhibition of Necroptosis by Simultaneously Targeting Multiple Effectors of the Pathway. ACS Chemical Biology, 2020, 15, 2702-2713.	1.6	22
20	Cotargeting BCL-2 and MCL-1 in high-risk B-ALL. Blood Advances, 2020, 4, 2762-2767.	2.5	28
21	Loss of RIPK3 does not impact MYC-driven lymphomagenesis or chemotherapeutic drug-induced killing of malignant lymphoma cells. Cell Death and Differentiation, 2020, 27, 2531-2533.	5.0	6
22	MARCH5 requires MTCH2 to coordinate proteasomal turnover of the MCL1:NOXA complex. Cell Death and Differentiation, 2020, 27, 2484-2499.	5.0	33
23	Deep profiling of apoptotic pathways with mass cytometry identifies a synergistic drug combination for killing myeloma cells. Cell Death and Differentiation, 2020, 27, 2217-2233.	5.0	29
24	Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood, 2020, 135, 791-803.	0.6	412
25	Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood, 2020, 135, 773-777.	0.6	115
26	Acquired Mutations in BAX Confer Resistance to BH3 Mimetics in Acute Myeloid Leukemia. Blood, 2020, 136, 7-8.	0.6	13
27	BAX-Mutated Clonal Hematopoiesis in Patients on Long-Term Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia. Blood, 2020, 136, 9-10.	0.6	4
28	Replication stress induces mitotic death through parallel pathways regulated by WAPL and telomere deprotection. Nature Communications, 2019, 10, 4224.	5.8	38
29	A small molecule interacts with VDAC2 to block mouse BAK-driven apoptosis. Nature Chemical Biology, 2019, 15, 1057-1066.	3.9	30
30	Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma. British Journal of Haematology, 2019, 186, e188-e191.	1.2	37
31	Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations. Nature Communications, 2019, 10, 2385.	5.8	139
32	Venetoclax for the treatment of mantle cell lymphoma. Annals of Lymphoma, 2019, 3, 4-4.	4.5	1
33	Multiple myeloma with 1q21 amplification is highly sensitive to MCL-1 targeting. Blood Advances, 2019, 3, 4202-4214.	2.5	60
34	Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia. Leukemia, 2019, 33, 905-917.	3.3	126
35	Dynamic molecular monitoring reveals that SWIâ€“SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nature Medicine, 2019, 25, 119-129.	15.2	147
36	Recipient BCL2 inhibition and NK cell ablation form part of a reduced intensity conditioning regime that improves allo-bone marrow transplantation outcomes. Cell Death and Differentiation, 2019, 26, 1516-1530.	5.0	10

#	Article	IF	Citations
37	KRAS-enhanced macropinocytosis and reduced FcRn-mediated recycling sensitize pancreatic cancer to albumin-conjugated drugs. Journal of Controlled Release, 2019, 296, 40-53.	4.8	39
38	Acquisition of the Recurrent Gly101Val Mutation in BCL2 Confers Resistance to Venetoclax in Patients with Progressive Chronic Lymphocytic Leukemia. Cancer Discovery, 2019, 9, 342-353.	7.7	306
39	Detection of Multiple Recurrent Novel BCL2 Mutations Co-Occurring with BCL2 Gly101Val in Patients with Chronic Lymphocytic Leukemia on Long Term Venetoclax. Blood, 2019, 134, 171-171.	0.6	5
40	BTK Leu528Trp - a Potential Secondary Resistance Mechanism Specific for Patients with Chronic Lymphocytic Leukemia Treated with the Next Generation BTK Inhibitor Zanubrutinib. Blood, 2019, 134, 170-170.	0.6	33
41	Loss of IRF4 Results in Multiple Myeloma Cell Apoptosis through the Transcriptional up-Regulation of the BH3-Only Proteins Bmf and BIM. Blood, 2019, 134, 3103-3103.	0.6	2
42	BAK/BAX-Mediated Apoptosis Is a Myc-Induced Roadblock toÂReprogramming. Stem Cell Reports, 2018, 10, 331-338.	2.3	16
43	Enhancing venetoclax activity in acute myeloid leukemia by co-targeting MCL1. Leukemia, 2018, 32, 303-312.	3.3	123
44	The Mitochondrial Apoptotic Effectors BAX/BAK Activate Caspase-3 and -7 to Trigger NLRP3 Inflammasome and Caspase-8 Driven IL-1Î² Activation. Cell Reports, 2018, 25, 2339-2353.e4.	2.9	164
45	VDAC2 enables BAX to mediate apoptosis and limit tumor development. Nature Communications, 2018, 9, 4976.	5.8	110
46	AMG 176, a Selective MCL1 Inhibitor, Is Effective in Hematologic Cancer Models Alone and in Combination with Established Therapies. Cancer Discovery, 2018, 8, 1582-1597.	7.7	310
47	CARM1-mediated methylation of protein arginine methyltransferase 5 represses human Î³-globin gene expression in erythroleukemia cells. Journal of Biological Chemistry, 2018, 293, 17454-17463.	1.6	20
48	Infection with flaviviruses requires BCLXL for cell survival. PLoS Pathogens, 2018, 14, e1007299.	2.1	28
49	IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood, 2018, 132, 2166-2178.	0.6	65
50	Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia. Clinical Cancer Research, 2017, 23, 4527-4533.	3.2	56
51	DR5 and caspase-8 are dispensable in ER stress-induced apoptosis. Cell Death and Differentiation, 2017, 24, 944-950.	5.0	65
52	Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood, 2017, 129, 3362-3370.	0.6	150
53	Essential role for Bim in mediating the apoptotic and antitumor activities of immunotoxins. Oncogene, 2017, 36, 4953-4962.	2.6	10
54	Anti-apoptotic proteins BCL-2, MCL-1 and A1 summate collectively to maintain survival of immune cell populations both in vitro and in vivo. Cell Death and Differentiation, 2017, 24, 878-888.	5.0	103

#	Article	IF	Citations
55	NatD promotes lung cancer progression by preventing histone H4 serine phosphorylation to activate Slug expression. Nature Communications, 2017, 8, 928.	5.8	69
56	Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. Science Translational Medicine, 2017, 9, .	5.8	148
57	Design, Synthesis, and Biological Activity of 1,2,3-Triazolobenzodiazepine BET Bromodomain Inhibitors. ACS Medicinal Chemistry Letters, 2017, 8, 1298-1303.	1.3	23
58	Targeting BCL2 With BH3 Mimetics: Basic Science and Clinical Application of Venetoclax in Chronic Lymphocytic Leukemia and Related B Cell Malignancies. Clinical Pharmacology and Therapeutics, 2017, 101, 89-98.	2.3	107
59	Defining a therapeutic window for kinase inhibitors in leukemia to avoid neutropenia. Oncotarget, 2017, 8, 57948-57963.	0.8	4
60	Identification of an activation site in Bak and mitochondrial Bax triggered by antibodies. Nature Communications, 2016, 7, 11734.	5.8	50
61	The BCL2 selective inhibitor venetoclax induces rapid onset apoptosis of CLL cells in patients via a TP53-independent mechanism. Blood, 2016, 127, 3215-3224.	0.6	242
62	Hepatocyte growth factor renders BRAF mutant human melanoma cell lines resistant to PLX4032 by downregulating the pro-apoptotic BH3-only proteins PUMA and BIM. Cell Death and Differentiation, 2016, 23, 2054-2062.	5.0	24
63	Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1. Blood, 2016, 128, 1834-1844.	0.6	127
64	MCL-1 is required throughout B-cell development and its loss sensitizes specific B-cell subsets to inhibition of BCL-2 or BCL-XL. Cell Death and Disease, 2016, 7, e2345-e2345.	2.7	53
65	Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood, 2016, 128, 1382-1395.	0.6	148
66	Eliminating Legionella by inhibiting BCL-XL to induce macrophage apoptosis. Nature Microbiology, 2016, 1, 15034.	5.9	75
67	The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 2016, 538, 477-482.	13.7	830
68	BET inhibition represses miR17-92 to drive BIM-initiated apoptosis of normal and transformed hematopoietic cells. Leukemia, 2016, 30, 1531-1541.	3.3	29
69	Small molecules targeting Mcl-1: the search for a silver bullet in cancer therapy. MedChemComm, 2016, 7, 778-787.	3.5	16
70	HSP90 activity is required for MLKL oligomerisation and membrane translocation and the induction of necroptotic cell death. Cell Death and Disease, 2016, 7, e2051-e2051.	2.7	123
71	Therapeutic Response to Non-genotoxic Activation of p53 by Nutlin3a Is Driven by PUMA-Mediated Apoptosis in Lymphoma Cells. Cell Reports, 2016, 14, 1858-1866.	2.9	35
72	Current challenges and novel treatment strategies in double hit lymphomas. Therapeutic Advances in Hematology, 2016, 7, 52-64.	1.1	20

#	Article	IF	Citations
73	Clinicopathological Features and Outcomes of Progression for Chronic Lymphocytic Leukaemia (CLL) Treated with the BCL2 Inhibitor Venetoclax. Blood, 2016, 128, 3223-3223.	0.6	2
74	The BIM deletion polymorphism: A paradigm of a permissive interaction between germline and acquired TKI resistance factors in chronic myeloid leukemia. Oncotarget, 2016, 7, 2721-2733.	0.8	16
75	Targeting the Pro-Survival BCL2 Proteins with BH3 Mimetic Compounds for Treating Multiple Myeloma. Blood, 2016, 128, 3293-3293.	0.6	0
76	The Role of BAX/BAK-Mediated Apoptosis for the Cytotoxic Action of Anti-Myeloma Agents. Blood, 2016, 128, 5706-5706.	0.6	0
77	A Chemical Screening Approach to Identify Novel Key Mediators of Erythroid Enucleation. PLoS ONE, 2015, 10, e0142655.	1.1	8
78	Prosurvival Bcl-2 family members reveal a distinct apoptotic identity between conventional and plasmacytoid dendritic cells. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, 4044-4049.	3.3	43
79	BCL2 inhibition in double hit lymphoma. Leukemia and Lymphoma, 2015, 56, 1928-1929.	0.6	1
80	Bclâ€2 Antagonists Kill Plasmacytoid Dendritic Cells From Lupusâ€Prone Mice and Dampen Interferonâ€± Production. Arthritis and Rheumatology, 2015, 67, 797-808.	2.9	43
81	Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy. Science Translational Medicine, 2015, 7, 279ra40.	5.8	430
82	A transgenic mouse model to inducibly target prosurvival Bcl2 proteins with selective BH3 peptides in vivo. Cell Death and Disease, 2015, 6, e1679-e1679.	2.7	1
83	A RIPK2 inhibitor delays NOD signalling events yet prevents inflammatory cytokine production. Nature Communications, 2015, 6, 6442.	5.8	112
84	Systematic Screening Identifies Dual PI3K and mTOR Inhibition as a Conserved Therapeutic Vulnerability in Osteosarcoma. Clinical Cancer Research, 2015, 21, 3216-3229.	3.2	58
85	Autoreactive T cells induce necrosis and not BCL-2-regulated or death receptor-mediated apoptosis or RIPK3-dependent necroptosis of transplanted islets in a mouse model of type 1 diabetes. Diabetologia, 2015, 58, 140-148.	2.9	32
86	Apoptotic Caspases Suppress mtDNA-Induced STING-Mediated Type I IFN Production. Cell, 2014, 159, 1549-1562.	13.5	698
87	Simplified Silvestrol Analogues with Potent Cytotoxic Activity. ChemMedChem, 2014, 9, 1556-1566.	1.6	16
88	Targeting BCL2 for the Treatment of Lymphoid Malignancies. Seminars in Hematology, 2014, 51, 219-227.	1.8	130
89	Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes and Development, 2014, 28, 58-70.	2.7	156
90	Prosurvival Bcl-2 family members affect autophagy only indirectly, by inhibiting Bax and Bak. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8512-8517.	3.3	166

#	Article	IF	Citations
91	Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 261-266.	3.3	43
92	Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia, 2014, 28, 1207-1215.	3.3	79
93	Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition. MedChemComm, 2014, 5, 1834-1842.	3.5	24
94	Further Insights into the Effects of Pre-organizing the BimBH3 Helix. ACS Chemical Biology, 2014, 9, 838-839.	1.6	26
95	De-Novo Designed Library of Benzoylureas as Inhibitors of BCL-X_L: Synthesis, Structural and Biochemical Characterization. Journal of Medicinal Chemistry, 2014, 57, 1323-1343.	2.9	33
96	Structure-Guided Rescaffolding of Selective Antagonists of BCL-X_L. ACS Medicinal Chemistry Letters, 2014, 5, 662-667.	1.3	37
97	197. Cytokine, 2014, 70, 75-76.	1.4	0
98	A Biosensor of Src Family Kinase Conformation by Exposable Tetracysteine Useful for Cell-Based Screening. ACS Chemical Biology, 2014, 9, 1426-1431.	1.6	9
99	Eradication of Acute Myeloid Leukemia Is Enhanced By Combined Bcl-2 and Mcl-1 Targeting. Blood, 2014, 124, 988-988.	0.6	2
100	ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.. Journal of Clinical Oncology, 2014, 32, 7015-7015.	0.8	42
101	Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. Blood, 2013, 122, 738-748.	0.6	53
102	ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nature Medicine, 2013, 19, 202-208.	15.2	2,426
103	Synthesis of Biotinylated Episilvestrol: Highly Selective Targeting of the Translation Factors eIF4AI/II. Organic Letters, 2013, 15, 1406-1409.	2.4	49
104	Bax Crystal Structures Reveal How BH3 Domains Activate Bax and Nucleate Its Oligomerization to Induce Apoptosis. Cell, 2013, 152, 519-531.	13.5	491
105	Structure-guided design of a selective BCL-XL inhibitor. Nature Chemical Biology, 2013, 9, 390-397.	3.9	324
106	Discovery of Potent and Selective Benzothiazole Hydrazone Inhibitors of Bcl-X_L. Journal of Medicinal Chemistry, 2013, 56, 5514-5540.	2.9	60
107	Stabilizing the Pro-Apoptotic BimBH3 Helix (BimSAHB) Does Not Necessarily Enhance Affinity or Biological Activity. ACS Chemical Biology, 2013, 8, 297-302.	1.6	123
108	BH3 mimetic therapy: an emerging and promising approach to treating chronic lymphocytic leukemia. Leukemia and Lymphoma, 2013, 54, 909-911.	0.6	2

#	Article	IF	Citations
109	MCMV-mediated Inhibition of the Pro-apoptotic Bak Protein Is Required for Optimal In Vivo Replication. PLoS Pathogens, 2013, 9, e1003192.	2.1	21
110	Proapoptotic Bak and Bax guard against fatal systemic and organ-specific autoimmune disease. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 2599-2604.	3.3	43
111	Variability of Inducible Expression across the Hematopoietic System of Tetracycline Transactivator Transgenic Mice. PLoS ONE, 2013, 8, e54009.	1.1	26
112	Selective Bcl-2 Inhibition With ABT-199 Is Highly Active Against Chronic Lymphocytic Leukemia (CLL) Irrespective Of TP53 Mutation Or Dysfunction. Blood, 2013, 122, 1304-1304.	0.6	10
113	Abstract A19: The selective targeting of cell survival pathways in leukemia. , 2013, , .		0
114	Sensitization of BCL-2â€“expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2766-2771.	3.3	173
115	Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737. Clinical Cancer Research, 2012, 18, 783-795.	3.2	98
116	Translation inhibitors induce cell death by multiple mechanisms and Mcl-1 reduction is only a minor contributor. Cell Death and Disease, 2012, 3, e409-e409.	2.7	42
117	Sheeppox Virus SPPV14 Encodes a Bcl-2-Like Cell Death Inhibitor That Counters a Distinct Set of Mammalian Proapoptotic Proteins. Journal of Virology, 2012, 86, 11501-11511.	1.5	41
118	Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood, 2012, 119, 4283-4290.	0.6	70
119	Synthesis and biological evaluation of a potent salicylihalamide A lactam analogue. Organic and Biomolecular Chemistry, 2012, 10, 8147.	1.5	11
120	The restricted binding repertoire of Bcl-B leaves Bim as the universal BH3-only prosurvival Bcl-2 protein antagonist. Cell Death and Disease, 2012, 3, e443-e443.	2.7	61
121	A Cluster of Interferon-Î³-Inducible p65 GTPases Plays a Critical Role in Host Defense against Toxoplasma gondii. Immunity, 2012, 37, 302-313.	6.6	311
122	The Dendritic Cell Receptor Clec9A Binds Damaged Cells via Exposed Actin Filaments. Immunity, 2012, 36, 646-657.	6.6	272
123	Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. Blood, 2012, 119, 5807-5816.	0.6	168
124	Total Synthesis of 2â€´,5â€´-Diepisilvestrol and Its C1â€´ Epimer: Key Structure Activity Relationships at C1â€´ and C2â€´. Journal of Natural Products, 2012, 75, 1500-1504.	1.5	19
125	Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. Journal of Clinical Oncology, 2012, 30, 488-496.	0.8	719
126	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. Journal of Experimental Medicine, 2011, 208, 2017-2031.	4.2	162

#	Article	IF	Citations
127	Quinazoline Sulfonamides as Dual Binders of the Proteins B-Cell Lymphoma 2 and B-Cell Lymphoma Extra Long with Potent Proapoptotic Cell-Based Activity. Journal of Medicinal Chemistry, 2011, 54, 1914-1926.	2.9	62
128	Bcl-xLâ€“inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets. Blood, 2011, 118, 1663-1674.	0.6	262
129	Overcoming blocks in apoptosis with BH3-mimetic therapy in haematological malignancies. Pathology, 2011, 43, 525-535.	0.3	36
130	Cyclicâ€AMPâ€dependent protein kinase A regulates apoptosis by stabilizing the BH3â€only protein Bim. EMBO Reports, 2011, 12, 77-83.	2.0	52
131	Sensitivity to antitubulin chemotherapeutics is regulated by MCL1 and FBW7. Nature, 2011, 471, 110-114.	13.7	682
132	Deerpox Virus Encodes an Inhibitor of Apoptosis That Regulates Bak and Bax. Journal of Virology, 2011, 85, 1922-1934.	1.5	40
133	Evaluation of the Bcl-2 family antagonist ABT-737 in collagen-induced arthritis. Journal of Leukocyte Biology, 2011, 90, 819-829.	1.5	12
134	Induction of antigenâ€specific effectorâ€phase tolerance following vaccination against a previously ignored Bâ€cell lymphoma. Immunology and Cell Biology, 2011, 89, 595-603.	1.0	13
135	Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. Journal of Cell Biology, 2011, 194, i12-i12.	2.3	0
136	Transgenic, inducible RNAi in megakaryocytes and platelets in mice. Journal of Thrombosis and Haemostasis, 2010, 8, 2751-2756.	1.9	11
137	Deubiquitinase USP9X stabilizes MCL1 and promotes tumour cell survival. Nature, 2010, 463, 103-107.	13.7	529
138	Apoptosis and non-inflammatory phagocytosis can be induced by mitochondrial damage without caspases. Cell Death and Differentiation, 2010, 17, 821-832.	5.0	33
139	Glucose Induces Pancreatic Islet Cell Apoptosis That Requires the BH3-Only Proteins Bim and Puma and Multi-BH Domain Protein Bax. Diabetes, 2010, 59, 644-652.	0.3	103
140	BH3 mimetics antagonizing restricted prosurvival Bcl-2 proteins represent another class of selective immune modulatory drugs. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10967-10971.	3.3	97
141	The BH3-Mimetic ABT-737 Induces Mast Cell Apoptosis In Vitro and In Vivo: Potential for Therapeutics. Journal of Immunology, 2010, 185, 2555-2562.	0.4	25
142	Structural Basis for Apoptosis Inhibition by Epstein-Barr Virus BHRF1. PLoS Pathogens, 2010, 6, e1001236.	2.1	99
143	Pro-apoptotic Bax is the major and Bak an auxiliary effector in cytokine deprivation-induced mast cell apoptosis. Cell Death and Disease, 2010, 1, e43-e43.	2.7	26
144	Megakaryocytes Possess a Functional Intrinsic Apoptosis Pathway That Must Be Restrained In Order to Survive and Produce Platelets. Blood, 2010, 116, 550-550.	0.6	0

#	Article	IF	Citations
145	Novel Bcl-2 Homology-3 Domain-like Sequences Identified from Screening Randomized Peptide Libraries for Inhibitors of the Pro-survival Bcl-2 Proteins. Journal of Biological Chemistry, 2009, 284, 31315-31326.	1.6	29
146	MEK/ERK-Mediated Phosphorylation of Bim Is Required to Ensure Survival of T and B Lymphocytes during Mitogenic Stimulation. Journal of Immunology, 2009, 183, 261-269.	0.4	76
147	Correction for Fletcher et al., Inaugural Article: Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 1678-1678.	3.3	0
148	The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia. Leukemia, 2009, 23, 2034-2041.	3.3	91
149	XIAP discriminates between type I and type II FAS-induced apoptosis. Nature, 2009, 460, 1035-1039.	13.7	421
150	Virally mediated inhibition of Bax in leukocytes promotes dissemination of murine cytomegalovirus. Cell Death and Differentiation, 2009, 16, 312-320.	5.0	35
151	Bax activation by Bim?. Cell Death and Differentiation, 2009, 16, 1187-1191.	5.0	79
152	Î²TrCP- and Rsk1/2-Mediated Degradation of BimEL Inhibits Apoptosis. Molecular Cell, 2009, 33, 109-116.	4.5	157
153	BH3-mimetics â€“ the solution to chemoresistance?. Leukemia and Lymphoma, 2009, 50, 1069-1072.	0.6	4
154	Two distinct pathways regulate platelet phosphatidylserine exposure and procoagulant function. Blood, 2009, 114, 663-666.	0.6	274
155	BH3-only proteins and their roles in programmed cell death. Oncogene, 2008, 27, S128-S136.	2.6	189
156	Controlling the cell death mediators Bax and Bak: puzzles and conundrums. Cell Cycle, 2008, 7, 39-44.	1.3	58
157	A novel BH3 ligand that selectively targets Mcl-1 reveals that apoptosis can proceed without Mcl-1 degradation. Journal of Cell Biology, 2008, 180, 341-355.	2.3	157
158	Apoptosis is triggered when prosurvival Bcl-2 proteins cannot restrain Bax. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 18081-18087.	3.3	162
159	Proapoptotic BH3-Only Protein Bid Is Essential For Death Receptorâ€“Induced Apoptosis of Pancreatic Î²-Cells. Diabetes, 2008, 57, 1284-1292.	0.3	85
160	Vaccinia virus anti-apoptotic F1L is a novel Bcl-2-like domain-swapped dimer that binds a highly selective subset of BH3-containing death ligands. Cell Death and Differentiation, 2008, 15, 1564-1571.	5.0	205
161	EGL-1 BH3 mutants reveal the importance of protein levels and target affinity for cell-killing potency. Cell Death and Differentiation, 2008, 15, 1609-1618.	5.0	10
162	In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 17961-17966.	3.3	137

#	Article	IF	Citations
163	Gefitinib-Induced Killing of NSCLC Cell Lines Expressing Mutant EGFR Requires BIM and Can Be Enhanced by BH3 Mimetics. PLoS Medicine, 2007, 4, e316.	3.9	297
164	Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 6217-6222.	3.3	397
165	Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. Journal of Cell Biology, 2007, 177, 277-287.	2.3	109
166	Programmed Anuclear Cell Death Delimits Platelet Life Span. Cell, 2007, 128, 1173-1186.	13.5	910
167	The BH3-Only Protein Bid Is Dispensable for DNA Damage- and Replicative Stress-Induced Apoptosis or Cell-Cycle Arrest. Cell, 2007, 129, 423-433.	13.5	189
168	Response: Does Bid Play a Role in the DNA Damage Response?. Cell, 2007, 130, 10-11.	13.5	14
169	A Structural Viral Mimic of Prosurvival Bcl-2:ÂAÂPivotal Role for Sequestering ProapoptoticÂBax and Bak. Molecular Cell, 2007, 25, 933-942.	4.5	125
170	Apoptosis Initiated When BH3 Ligands Engage Multiple Bcl-2 Homologs, Not Bax or Bak. Science, 2007, 315, 856-859.	6.0	1,021
171	(Î±/Î²+Î±)-Peptide Antagonists of BH3 Domain/Bcl-xL Recognition:â€‰ Toward General Strategies for Foldamer-Based Inhibition of Proteinâ^'Protein Interactions. Journal of the American Chemical Society, 2007, 129, 139-154.	6.6	160
172	Interleukin 15â€“mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nature Immunology, 2007, 8, 856-863.	7.0	231
173	Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death and Differentiation, 2007, 14, 128-136.	5.0	202
174	Modified vaccinia virus Ankara protein F1L is a novel BH3-domain-binding protein and acts together with the early viral protein E3L to block virus-associated apoptosis. Cell Death and Differentiation, 2006, 13, 109-118.	5.0	58
175	CED-4 forms a 2â€‰:â€‰2 heterotetrameric complex with CED-9 until specifically displaced by EGL-1 or CED-13. Cell Death and Differentiation, 2006, 13, 426-434.	5.0	23
176	BH3-only proteins: orchestrating cell death. Cell Death and Differentiation, 2006, 13, 1268-1271.	5.0	21
177	How the Bcl-2 family of proteins interact to regulate apoptosis. Cell Research, 2006, 16, 203-213.	5.7	301
178	The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006, 10, 389-399.	7.7	1,149
179	Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 14907-14912.	3.3	310
180	FADD and caspase-8 are required for cytokine-induced proliferation of hemopoietic progenitor cells. Blood, 2005, 106, 1581-1589.	0.6	56

#	Article	IF	Citations
181	Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16182-16187.	3.3	133
182	Solution Structure of Prosurvival Mcl-1 and Characterization of Its Binding by Proapoptotic BH3-only Ligands. Journal of Biological Chemistry, 2005, 280, 4738-4744.	1.6	187
183	Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes and Development, 2005, 19, 1294-1305.	2.7	1,071
184	Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic Function. Molecular Cell, 2005, 17, 393-403.	4.5	1,639
185	Subversion of the Bcl-2 Life/Death Switch in Cancer Development and Therapy. Cold Spring Harbor Symposia on Quantitative Biology, 2005, 70, 469-477.	2.0	26
186	Modifications and intracellular trafficking of FADD/MORT1 and caspase-8 after stimulation of T lymphocytes. Cell Death and Differentiation, 2004, 11, 724-736.	5.0	48
187	Nuclear localisation of FADD â€“ rebuttal. Cell Death and Differentiation, 2004, 11, 1362-1363.	5.0	5
188	Protein hijacking. Cancer Cell, 2004, 5, 107-108.	7.7	10
189	Localization of dynein light chains 1 and 2 and their pro-apoptotic ligands. Biochemical Journal, 2004, 377, 597-605.	1.7	65
190	The structure of Bcl-w reveals a role for the C-terminal residues in modulating biological activity. EMBO Journal, 2003, 22, 1497-1507.	3.5	151
191	Bfk: a novel weakly proapoptotic member of the Bcl-2 protein family with a BH3 and a BH2 region. Cell Death and Differentiation, 2003, 10, 185-192.	5.0	45
192	The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene, 2003, 22, 8590-8607.	2.6	1,342
193	Proapoptotic BH3-only proteins trigger membrane integration of prosurvival Bcl-w and neutralize its activity. Journal of Cell Biology, 2003, 162, 877-888.	2.3	104
194	The Bcl-2-regulated apoptotic pathway. Journal of Cell Science, 2003, 116, 4053-4056.	1.2	206
195	Direct addition of BimL to mitochondria does not lead to cytochromecrelease. FEBS Letters, 2002, 522, 29-34.	1.3	41
196	Prospects for targeting the Bcl-2 family of proteins to develop novel cytotoxic drugs. Biochemical Pharmacology, 2002, 64, 851-863.	2.0	130
197	Caspase-2 is not required for thymocyte or neuronal apoptosis even though cleavage of caspase-2 is dependent on both Apaf-1 and caspase-9. Cell Death and Differentiation, 2002, 9, 832-841.	5.0	170
198	Pro-apoptotic BH3-only Bcl-2 family members in vertebrate model organisms suitable for genetic experimentation. Cell Death and Differentiation, 2002, 9, 1163-1166.	5.0	31

#	Article	IF	Citations
199	Apoptosis initiated by Bcl-2-regulated caspase activation independently of the cytochrome c/Apaf-1/caspase-9 apoptosome. Nature, 2002, 419, 634-637.	13.7	517
200	Rapid Selection against Truncation Mutants in Yeast Reverse Two-Hybrid Screens. BioTechniques, 2001, 30, 984-988.	0.8	12
201	Gene structure, alternative splicing, and chromosomal localization of pro-apoptotic Bcl-2 relative Bim. Mammalian Genome, 2001, 12, 163-168.	1.0	133
202	Tissue expression and subcellular localization of the pro-survival molecule Bcl-w. Cell Death and Differentiation, 2001, 8, 486-494.	5.0	94
203	Bmf: A Proapoptotic BH3-Only Protein Regulated by Interaction with the Myosin V Actin Motor Complex, Activated by Anoikis. Science, 2001, 293, 1829-1832.	6.0	555
204	Bcl-2 does not inhibit cell death induced by the physiological Fas ligand: implications for the existence of typeâ€‰I and typeâ€‰II cells. Cell Death and Differentiation, 2000, 7, 754-755.	5.0	36
205	Apoptosis and cell division. Current Opinion in Cell Biology, 2000, 12, 257-263.	2.6	66
206	Fas Ligand-Induced c-Jun Kinase Activation in Lymphoid Cells Requires Extensive Receptor Aggregation But Is Independent of DAXX, and Fas-Mediated Cell Death Does Not Involve DAXX, RIP, or RAIDD. Journal of Immunology, 2000, 165, 1337-1343.	0.4	61
207	Pro-Apoptotic Apoptosis Proteaseâ€“Activating Factor 1 (Apaf-1) Has a Cytoplasmic Localization Distinct from Bcl-2 or Bcl-XL. Journal of Cell Biology, 2000, 149, 623-634.	2.3	132
208	Transgenic overexpression of human Bcl-2 in islet Î² cells inhibits apoptosis but does not prevent autoimmune destruction. International Immunology, 2000, 12, 9-17.	1.8	56
209	Debcl, a Proapoptotic Bcl-2 Homologue, Is a Component of the Drosophila melanogaster Cell Death Machinery. Journal of Cell Biology, 2000, 148, 703-714.	2.3	161
210	The Proapoptotic BH3-Only Protein Bim Is Expressed in Hematopoietic, Epithelial, Neuronal, and Germ Cells. American Journal of Pathology, 2000, 157, 449-461.	1.9	214
211	BH3-Only Proteinsâ€”Essential Initiators of Apoptotic Cell Death. Cell, 2000, 103, 839-842.	13.5	964
212	The Role of Bim, a Proapoptotic BH3â€Only Member of the Bclâ€2 Family, in Cellâ€Death Control. Annals of the New York Academy of Sciences, 2000, 917, 541-548.	1.8	113
213	The Role of the Proâ€Apoptotic Bclâ€2 Family Member Bim in Physiological Cell Death. Annals of the New York Academy of Sciences, 2000, 926, 83-89.	1.8	28
214	Bcl-2 family members do not inhibit apoptosis by binding the caspase activator Apaf-1. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 9683-9688.	3.3	142
215	Activation of Fas by FasL induces apoptosis by a mechanism that cannot be blocked by Bcl-2 or Bcl-xL. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 14871-14876.	3.3	296
216	Survival activity of Bcl-2 homologs Bcl-w and A1 only partially correlates with their ability to bind pro-apoptotic family members. Cell Death and Differentiation, 1999, 6, 525-532.	5.0	45

#	Article	IF	Citations
217	Induction of cell death by tumour necrosis factor (TNF) receptor 2,CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF. EMBO Journal, 1999, 18, 3034-3043.	3.5	255
218	Proapoptotic Bcl-2 Relative Bim Required for Certain Apoptotic Responses, Leukocyte Homeostasis, and to Preclude Autoimmunity. Science, 1999, 286, 1735-1738.	6.0	1,386
219	The Proapoptotic Activity of the Bcl-2 Family Member Bim Is Regulated by Interaction with the Dynein Motor Complex. Molecular Cell, 1999, 3, 287-296.	4.5	964
220	Control of Apoptosis in Hematopoietic Cells by the Bcl-2 Family of Proteins. Cold Spring Harbor Symposia on Quantitative Biology, 1999, 64, 351-358.	2.0	29
221	Bim: a novel member of the Bcl-2 family that promotes apoptosis. EMBO Journal, 1998, 17, 384-395.	3.5	1,005
222	The conserved N-terminal BH4 domain of Bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO Journal, 1998, 17, 1029-1039.	3.5	210
223	Rapid Hybridoma Screening Method for the Identification of Monoclonal Antibodies to Low-Abundance Cytoplasmic Proteins. BioTechniques, 1998, 25, 824-830.	0.8	39
224	Bcl-2, Bcl-xL and adenovirus protein E1B19kD are functionally equivalent in their ability to inhibit cell death. Oncogene, 1997, 14, 405-414.	2.6	244
225	The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. Biochimica Et Biophysica Acta: Reviews on Cancer, 1997, 1333, F151-F178.	3.3	85
226	The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO Journal, 1997, 16, 4628-4638.	3.5	290
227	The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry.. EMBO Journal, 1996, 15, 6979-6990.	3.5	319
228	The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO Journal, 1996, 15, 6979-90.	3.5	136
229	bcl-w, a novel member of the bcl-2 family, promotes cell survival. Oncogene, 1996, 13, 665-75.	2.6	235
230	Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis.. EMBO Journal, 1995, 14, 6136-6147.	3.5	643
231	Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO Journal, 1995, 14, 6136-47.	3.5	245
232	Plasma membrane-targeted ras GTPase-activating protein is a potent suppressor of p21ras function.. Molecular and Cellular Biology, 1993, 13, 2420-2431.	1.1	73
233	Plasma Membrane-Targeted ras GTPase-Activating Protein Is a Potent Suppressor of p21^{ras} Function. Molecular and Cellular Biology, 1993, 13, 2420-2431.	1.1	45
234	Effects of anti-TNF monoclonal antibody infusion in patients with hairy cell leukaemia. British Journal of Haematology, 1992, 81, 231-234.	1.2	12